Completed PHASE1 INTERVENTIONAL 4-arm NCT04561245

ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

A Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of ALT-801 in Healthy Overweight and Obese Volunteers

Sponsor: Altimmune, Inc.

Conditions Nonalcoholic Steatohepatitis Obesity

Interventions ALT-801 Placebo

Updated 8 times since 2020 Last updated: Jun 18, 2025 Started: Nov 10, 2020 Primary completion: Oct 29, 2021 Completion: Oct 29, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Nonalcoholic Steatohepatitis and Obesity and is currently completed. Altimmune, Inc. leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

8 versions recorded

Jul 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Jul 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Sep 2021 — Dec 2021 [monthly]

Recruiting PHASE1

▶ Show 3 earlier versions

Feb 2021 — Sep 2021 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Feb 2021 [monthly]

Not Yet Recruiting PHASE1
Oct 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Altimmune, Inc.

Data source: Altimmune, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Herston, Australia